Stephens analyst Sudan Loganathan lowered the firm’s price target on Immunome (IMNM) to $30 from $33 and keeps an Overweight rating on the shares. The firm updated estimates following the company’s Q4 business update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $39 from $35 at JPMorgan
- Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
- Immunome reports FY25 EPS ($2.43), consensus ($2.21)
- Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls